Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2012

Open Access 01-12-2012 | Research article

CYP1A2 rs762551 polymorphism contributes to cancer susceptibility: a meta-analysis from 19 case-control studies

Authors: Hongge Wang, Zhi Zhang, Sugui Han, Yujuan Lu, Fumin Feng, Juxiang Yuan

Published in: BMC Cancer | Issue 1/2012

Login to get access

Abstract

Background

Genetic polymorphism (rs762551A>C) in gene encoding cytochrome P450 1A2 (CYP1A2) has been shown to influence the inducibility of CYP1A2 expression and thus might be associated with risk of several types of human cancer. However, the results of previous studies on the associations of this polymorphism with risk of cancer are not all consistent. To clarify the potential contribution of CYP1A2 rs762551 to cancer risk, we performed a meta-analysis of the published case–control studies.

Methods

We used PubMed, Embase, OVID, ScienceDirect, and Chinese National Knowledge Infrastructure databases to identify the related publications for this meta-analysis. The pooled odds ratio (OR) and 95% confidence interval (CI) were calculated using random effect model to evaluate the association of rs762551 with cancer risk. A χ 2-based Q-test was used to examine the heterogeneity assumption and the funnel plot and Egger’s test were used to examine the potential publication bias. The leave-one-out sensitivity analysis was conducted to determine whether our assumptions or decisions have a major effect on the results of the review.

Results

Our analysis of 19 eligible case–control studies showed a significant association between rs762551C variant with risk of cancer in the genetic model of CC versus AA (OR = 1.30, 95% CI = 1.02-1.64) and the dominant model (OR = 1.19, 95% CI = 1.04-1.36). In subgroup analysis based on ethnicity, the rs762551CC genotype was associated with increased cancer risk (OR = 1.29, 95% CI = 1.27-1.63 in co-dominate model and OR = 1.17, 95% CI = 1.02-1.34 in dominant model in Caucasians, but not in Asians and the mixed population.

Conclusion

These results suggested that CYP1A2 rs762551 polymorphism is likely to be associated with susceptibility to cancer in Caucasians.
Appendix
Available only for authorised users
Literature
1.
Rodriguez-Antona C, Gomez A, Karlgren M, Sim SC, Ingelman-Sundberg M: Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment. Hum Genet. 2010, 127 (1): 1-17. 10.1007/s00439-009-0748-0.CrossRefPubMed
2.
Eaton DL, Gallagher EP, Bammler TK, Kunze KL: Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity. Pharmacogenetics. 1995, 5 (5): 259-274. 10.1097/00008571-199510000-00001.CrossRefPubMed
3.
Landi MT, Sinha R, Lang NP, Kadlubar FF: Human cytochrome P4501A2. IARC Sci Publ. 1999, 148: 173-195.PubMed
4.
Jorge-Nebert LF, Jiang Z, Chakraborty R, Watson J, Jin L, McGarvey ST, Deka R, Nebert DW: Analysis of human CYP1A1 and CYP1A2 genes and their shared bidirectional promoter in eight world populations. Hum Mutat. 2010, 31 (1): 27-40. 10.1002/humu.21132.CrossRefPubMedPubMedCentral
5.
Aitchison KJ, Gonzalez FJ, Quattrochi LC, Sapone A, Zhao JH, Zaher H, Elizondo G, Bryant C, Munro J, Collier DA, et al: Identification of novel polymorphisms in the 5' flanking region of CYP1A2, characterization of interethnic variability, and investigation of their functional significance. Pharmacogenetics. 2000, 10 (8): 695-704. 10.1097/00008571-200011000-00004.CrossRefPubMed
6.
Sterling KM, Cutroneo KR: Constitutive and inducible expression of cytochromes P4501A (CYP1A1 and CYP1A2) in normal prostate and prostate cancer cells. J Cell Biochem. 2004, 91 (2): 423-429. 10.1002/jcb.10753.CrossRefPubMed
7.
Khvostova EP, Pustylnyak VO, Gulyaeva LF: Genetic Polymorphism of Estrogen Metabolizing Enzymes in Siberian Women with Breast Cancer. Genet Test Mol Biomarkers. 2012, 16 (3): 167-173. 10.1089/gtmb.2011.0131.CrossRefPubMed
8.
Singh AP, Pant MC, Ruwali M, Shah PP, Prasad R, Mathur N, Parmar D: Polymorphism in cytochrome P450 1A2 and their interaction with risk factors in determining risk of squamous cell lung carcinoma in men. Cancer Biomark. 2010, 8 (6): 351-359.PubMed
9.
B'Chir F, Pavanello S, Knani J, Boughattas S, Arnaud MJ, Saguem S: CYP1A2 genetic polymorphisms and adenocarcinoma lung cancer risk in the Tunisian population. Life Sci. 2009, 84 (21–22): 779-784.CrossRefPubMed
10.
Gemignani F, Landi S, Szeszenia-Dabrowska N, Zaridze D, Lissowska J, Rudnai P, Fabianova E, Mates D, Foretova L, Janout V, et al: Development of lung cancer before the age of 50: the role of xenobiotic metabolizing genes. Carcinogenesis. 2007, 28 (6): 1287-1293. 10.1093/carcin/bgm021.CrossRefPubMed
11.
Landi S, Gemignani F, Moreno V, Gioia-Patricola L, Chabrier A, Guino E, Navarro M, de Oca J, Capella G, Canzian F: A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of colorectal cancer. Pharmacogenet Genomics. 2005, 15 (8): 535-546. 10.1097/01.fpc.0000165904.48994.3d.CrossRefPubMed
12.
Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, Kamataki T: Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem. 1999, 125 (4): 803-808. 10.1093/oxfordjournals.jbchem.a022352.CrossRefPubMed
13.
Gunes A, Ozbey G, Vural EH, Uluoglu C, Scordo MG, Zengil H, Dahl ML: Influence of genetic polymorphisms, smoking, gender and age on CYP1A2 activity in a Turkish population. Pharmacogenomics. 2009, 10 (5): 769-778. 10.2217/pgs.09.22.CrossRefPubMed
14.
Ghotbi R, Christensen M, Roh HK, Ingelman-Sundberg M, Aklillu E, Bertilsson L: Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol. 2007, 63 (6): 537-546. 10.1007/s00228-007-0288-2.CrossRefPubMed
15.
Wang H, Yamamoto JF, Caberto C, Saltzman B, Decker R, Vogt TM, Yokochi L, Chanock S, Wilkens LR, Le Marchand L: Genetic variation in the bioactivation pathway for polycyclic hydrocarbons and heterocyclic amines in relation to risk of colorectal neoplasia. Carcinogenesis. 2010, 32 (2): 203-209.CrossRefPubMedPubMedCentral
16.
Sangrajrang S, Sato Y, Sakamoto H, Ohnami S, Laird NM, Khuhaprema T, Brennan P, Boffetta P, Yoshida T: Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women. Int J Cancer. 2009, 125 (4): 837-843. 10.1002/ijc.24434.CrossRefPubMed
17.
Kobayashi M, Otani T, Iwasaki M, Natsukawa S, Shaura K, Koizumi Y, Kasuga Y, Sakamoto H, Yoshida T, Tsugane S: Association between dietary heterocyclic amine levels, genetic polymorphisms of NAT2, CYP1A1, and CYP1A2 and risk of stomach cancer: a hospital-based case–control study in Japan. Gastric Cancer. 2009, 12 (4): 198-205. 10.1007/s10120-009-0523-x.CrossRefPubMed
18.
Osawa Y, Osawa KK, Miyaishi A, Higuchi M, Tsutou A, Matsumura S, Tabuchi Y, Tsubota N, Takahashi J: NAT2 and CYP1A2 polymorphisms and lung cancer risk in relation to smoking status. Asian Pac J Cancer Prev. 2007, 8 (1): 103-108.PubMed
19.
DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials. 1986, 7 (3): 177-188. 10.1016/0197-2456(86)90046-2.CrossRefPubMed
20.
Schmidt FL, Oh IS, Hayes TL: Fixed- versus random-effects models in meta-analysis: model properties and an empirical comparison of differences in results. Br J Math Stat Psychol. 2009, 62 (Pt 1): 97-128.CrossRefPubMed
21.
Berkey CS, Hoaglin DC, Mosteller F, Colditz GA: A random-effects regression model for meta-analysis. Stat Med. 1995, 14 (4): 395-411. 10.1002/sim.4780140406.CrossRefPubMed
22.
Hysong SJ: Meta-analysis: audit and feedback features impact effectiveness on care quality. Med Care. 2009, 47 (3): 356-363. 10.1097/MLR.0b013e3181893f6b.CrossRefPubMedPubMedCentral
23.
Biljana M, Jelena M, Branislav J, Milorad R: Bias in meta-analysis and funnel plot asymmetry. Stud Health Technol Inform. 1999, 68: 323-328.PubMed
24.
Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997, 315 (7109): 629-634. 10.1136/bmj.315.7109.629.CrossRefPubMedPubMedCentral
25.
Agundez JA: Cytochrome P450 gene polymorphism and cancer. Curr Drug Metab. 2004, 5 (3): 211-224. 10.2174/1389200043335621.CrossRefPubMed
26.
Han XM, Zhou HH: Polymorphism of CYP450 and cancer susceptibility. Acta Pharmacol Sin. 2000, 21 (8): 673-679.PubMed
27.
Jernstrom H, Henningson M, Johansson U, Olsson H: Coffee intake and CYP1A2*1F genotype predict breast volume in young women: implications for breast cancer. Br J Cancer. 2008, 99 (9): 1534-1538. 10.1038/sj.bjc.6604687.CrossRefPubMedPubMedCentral
28.
Tsukino H, Kuroda Y, Nakao H, Imai H, Inatomi H, Osada Y, Katoh T: Cytochrome P450 (CYP) 1A2, sulfotransferase (SULT) 1A1, and N-acetyltransferase (NAT) 2 polymorphisms and susceptibility to urothelial cancer. J Cancer Res Clin Oncol. 2004, 130 (2): 99-106. 10.1007/s00432-003-0512-0.CrossRefPubMed
29.
Sachse C, Bhambra U, Smith G, Lightfoot TJ, Barrett JH, Scollay J, Garner RC, Boobis AR, Wolf CR, Gooderham NJ: Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism. Br J Clin Pharmacol. 2003, 55 (1): 68-76. 10.1046/j.1365-2125.2003.01733.x.CrossRefPubMedPubMedCentral
30.
Kiss I, Orsos Z, Gombos K, Bogner B, Csejtei A, Tibold A, Varga Z, Pazsit E, Magda I, Zolyomi A, et al: Association between allelic polymorphisms of metabolizing enzymes (CYP 1A1, CYP 1A2, CYP 2E1, mEH) and occurrence of colorectal cancer in Hungary. Anticancer Res. 2007, 27 (4C): 2931-2937.PubMed
31.
MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk: Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women. Breast Cancer Res Treat. 2010, 119 (2): 463-474.CrossRef
32.
Altayli E, Gunes S, Yilmaz AF, Goktas S, Bek Y: CYP1A2, CYP2D6, GSTM1, GSTP1, and GSTT1 gene polymorphisms in patients with bladder cancer in a Turkish population. Int Urol Nephrol. 2009, 41 (2): 259-266. 10.1007/s11255-008-9444-6.CrossRefPubMed
33.
Aldrich MC, Selvin S, Hansen HM, Barcellos LF, Wrensch MR, Sison JD, Kelsey KT, Buffler PA, Quesenberry CP, Seldin MF, et al: CYP1A1/2 haplotypes and lung cancer and assessment of confounding by population stratification. Cancer Res. 2009, 69 (6): 2340-2348. 10.1158/0008-5472.CAN-08-2576.CrossRefPubMedPubMedCentral
34.
Suzuki H, Morris JS, Li Y, Doll MA, Hein DW, Liu J, Jiao L, Hassan MM, Day RS, Bondy ML, et al: Interaction of the cytochrome P4501A2, SULT1A1 and NAT gene polymorphisms with smoking and dietary mutagen intake in modification of the risk of pancreatic cancer. Carcinogenesis. 2008, 29 (6): 1184-1191. 10.1093/carcin/bgn085.CrossRefPubMedPubMedCentral
35.
Saebo M, Skjelbred CF, Brekke Li K, Bowitz Lothe IM, Hagen PC, Johnsen E, Tveit KM, Kure EH: CYP1A2 164 A-->C polymorphism, cigarette smoking, consumption of well-done red meat and risk of developing colorectal adenomas and carcinomas. Anticancer Res. 2008, 28 (4C): 2289-2295.PubMed
36.
Yoshida K, Osawa K, Kasahara M, Miyaishi A, Nakanishi K, Hayamizu S, Osawa Y, Tsutou A, Tabuchi Y, Shimada E, et al: Association of CYP1A1, CYP1A2, GSTM1 and NAT2 gene polymorphisms with colorectal cancer and smoking. Asian Pac J Cancer Prev. 2007, 8 (3): 438-444.PubMed
37.
Kotsopoulos J, Ghadirian P, El-Sohemy A, Lynch HT, Snyder C, Daly M, Domchek S, Randall S, Karlan B, Zhang P, et al: The CYP1A2 genotype modifies the association between coffee consumption and breast cancer risk among BRCA1 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2007, 16 (5): 912-916. 10.1158/1055-9965.EPI-06-1074.CrossRefPubMed
38.
Long JR, Egan KM, Dunning L, Shu XO, Cai Q, Cai H, Dai Q, Holtzman J, Gao YT, Zheng W: Population-based case–control study of AhR (aryl hydrocarbon receptor) and CYP1A2 polymorphisms and breast cancer risk. Pharmacogenet Genomics. 2006, 16 (4): 237-243. 10.1097/01.fpc.0000189803.34339.ed.CrossRefPubMed
39.
Li D, Jiao L, Li Y, Doll MA, Hein DW, Bondy ML, Evans DB, Wolff RA, Lenzi R, Pisters PW, et al: Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer. Carcinogenesis. 2006, 27 (1): 103-111.CrossRefPubMed
40.
Bae SY, Choi SK, Kim KR, Park CS, Lee SK, Roh HK, Shin DW, Pie JE, Woo ZH, Kang JH: Effects of genetic polymorphisms of MDR1, FMO3 and CYP1A2 on susceptibility to colorectal cancer in Koreans. Cancer Sci. 2006, 97 (8): 774-779. 10.1111/j.1349-7006.2006.00241.x.CrossRefPubMed
41.
Goodman MT, Tung KH, McDuffie K, Wilkens LR, Donlon TA: Association of caffeine intake and CYP1A2 genotype with ovarian cancer. Nutr Cancer. 2003, 46 (1): 23-29. 10.1207/S15327914NC4601_03.CrossRefPubMed
42.
Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med. 2002, 21 (11): 1539-1558. 10.1002/sim.1186.CrossRefPubMed
43.
Smith E: Uncertainty analysis. Encyclopedia of Environmetrics. volume 4. Edited by: EI-Shaarawi AH, Piegorsch WW. 2002, Wiley, Chichester, 2283-2297.
44.
Risch N, Merikangas K: The future of genetic studies of complex human diseases. Science. 1996, 273 (5281): 1516-1517. 10.1126/science.273.5281.1516.CrossRefPubMed
45.
Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN: Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet. 2003, 33 (2): 177-182. 10.1038/ng1071.CrossRefPubMed
46.
Munafo MR, Flint J: Meta-analysis of genetic association studies. Trends Genet. 2004, 20 (9): 439-444. 10.1016/j.tig.2004.06.014.CrossRefPubMed
47.
Tao L, Xiang YB, Chan KK, Wang R, Gao YT, Yu MC, Yuan JM: Cytochrome P4501A2 phenotype and bladder cancer risk: the Shanghai bladder cancer study. Int J Cancer. 2011, 130 (5): 1174-1183.CrossRefPubMedPubMedCentral
48.
Chen X, Wang L, Zhi L, Zhou G, Wang H, Zhang X, Hao B, Zhu Y, Cheng Z, He F: The G-113A polymorphism in CYP1A2 affects the caffeine metabolic ratio in a Chinese population. Clin Pharmacol Ther. 2005, 78 (3): 249-259. 10.1016/j.clpt.2005.05.012.CrossRefPubMed
49.
Sachse C, Brockmoller J, Bauer S, Roots I: Functional significance of a C–>A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol. 1999, 47 (4): 445-449.CrossRefPubMedPubMedCentral
50.
Gilliland FD: Ethnic differences in cancer incidence: a marker for inherited susceptibility?. Environ Health Perspect. 1997, 105 (Suppl 4): 897-900. 10.1289/ehp.97105s4897.CrossRefPubMedPubMedCentral
Metadata
Title
CYP1A2 rs762551 polymorphism contributes to cancer susceptibility: a meta-analysis from 19 case-control studies
Authors
Hongge Wang
Zhi Zhang
Sugui Han
Yujuan Lu
Fumin Feng
Juxiang Yuan
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2012
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-12-528

Other articles of this Issue 1/2012

BMC Cancer 1/2012 Go to the issue

Research article

Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy

Research article

Sorafenib modulates the radio sensitivity of hepatocellular carcinoma cells in vitro in a schedule-dependent manner

Research article

RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls

Research article

The mitochondrial transporter SLC25A43 is frequently deleted and may influence cell proliferation in HER2-positive breast tumors

Research article

Patterns of regional lymph node metastasis of nasopharyngeal carcinoma: A meta-analysis of clinical evidence

Research article

Engineered measles virus Edmonston strain used as a novel oncolytic viral system against human hepatoblastoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits